Caprock Group LLC Makes New Investment in Amgen Inc. $AMGN

Caprock Group LLC acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 21,401 shares of the medical research company’s stock, valued at approximately $6,209,000.

Several other large investors have also made changes to their positions in AMGN. Legacy Investment Solutions LLC purchased a new position in shares of Amgen during the second quarter worth $27,000. Evelyn Partners Investment Management LLP acquired a new stake in Amgen during the 2nd quarter worth about $32,000. Howard Hughes Medical Institute purchased a new position in shares of Amgen during the 2nd quarter valued at about $32,000. Quaker Wealth Management LLC lifted its holdings in shares of Amgen by 200.0% in the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after buying an additional 240 shares during the period. Finally, Cloud Capital Management LLC purchased a new stake in shares of Amgen in the third quarter worth about $34,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Performance

NASDAQ:AMGN opened at $364.65 on Wednesday. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The stock has a market capitalization of $196.36 billion, a PE ratio of 25.63, a P/E/G ratio of 3.85 and a beta of 0.46. Amgen Inc. has a fifty-two week low of $261.43 and a fifty-two week high of $385.12. The company has a fifty day moving average of $335.74 and a two-hundred day moving average of $312.39.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the previous year, the company earned $5.31 earnings per share. The company’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.8%. Amgen’s payout ratio is currently 66.90%.

Analysts Set New Price Targets

Several research analysts recently weighed in on AMGN shares. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Truist Financial boosted their target price on shares of Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. Wall Street Zen downgraded shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Saturday. HSBC restated a “buy” rating and set a $425.00 price target on shares of Amgen in a research report on Wednesday, December 10th. Finally, Royal Bank Of Canada increased their target price on shares of Amgen from $335.00 to $360.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $353.39.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the firm’s stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares in the company, valued at $2,436,703.50. This trade represents a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.69% of the stock is currently owned by company insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.